Novartis to Acquire Advanced Accelerator Applications for $3.9B

Novartis said today it intends to acquire Advanced Accelerator Applications (AAA) for $3.9 billion cash, in a deal designed to expand the buyer’s neuroendocrine tumor (NET) pipeline with radiopharmaceutical candidates led by the first-in-class RadioLigand Therapy (RLT) Lutathera ® ( 177 Lu-Dotatate), now under FDA re-review.Novartis said the deal would also boost its oncology portfolio, both short-term through product launches and long-term through a new technology platform it said had